Pioneering Genomic Discoveries
Explore our cutting-edge research programs spanning cancer genomics, synthetic biology, rare diseases, and pharmacogenomics.
Cancer Genomics
Our cancer genomics program focuses on identifying genetic mutations and biomarkers that drive tumor development and progression. Through comprehensive whole-genome sequencing and advanced bioinformatics analysis, we are developing novel approaches to early detection and personalized treatment strategies.
Key Highlights
- Identified 47 novel genetic markers for early-stage lung cancer detection
- Developed AI-powered tumor classification system with 98.5% accuracy
- Published 23 peer-reviewed papers in top-tier oncology journals
Research Progress Over Time
Recent Publications
Novel Biomarkers in Non-Small Cell Lung Cancer
Nature Genetics
Machine Learning Approaches to Tumor Classification
Cancer Research
Genomic Landscape of Metastatic Breast Cancer
Cell
Research Milestones
Laboratory Founded
Genomic Sentinel established with initial seed funding
First Major Discovery
Identified novel biomarker panel for early cancer detection
Clinical Partnerships
Established collaborations with 15 major medical centers
AI Platform Launch
Deployed proprietary AI system for genomic analysis
Global Expansion
Expanded research capabilities globally
Breakthrough Therapy
Gene therapy candidate enters Phase II clinical trials
Industry Recognition
Awarded Global Innovation Prize for genomic research